PRS5 ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE A TOPIC CONDITIONS IN UK: COHORT STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE  by Punekar, YS et al.
Therapeutic Chemical Classiﬁcation group. Subjects with a hos-
pital admission for asthma (ICD-9 cod.493) and/or a prescrip-
tion of drugs with indication for an allergenic disease (R03DC,
R03BC) were excluded. RESULTS: A cohort of 12,212 COPD
affected patients (51.5% males) was selected, 11,726 received
drug prescription and 1,405 were hospitalized. Only the 7 % of
the cohort was recognized from both electronic databases. Strik-
ingly, the 39% of subjects selected with a hospital admission for
COPD did not received drugs chronic prescription. The esti-
mated prevalence in adult population (>= 45 years old) was
6,3% and was higher in males (7.1%) than in females (5.7%).
Stratifying by age the prevalence was highest in subjects with
more than 75 years and is twice in males. CONCLUSIONS:
From the administrative database it was possible to provide an
estimation of the prevalence of COPD in a particular area of
Campania. Further research will validate our results, in particu-
lar, in future we will be able to describe therapeutic proﬁles of
patients and we will try to understand why a high percentage of
subjects with an hospital admission for Chronic Bronchitis
receive no medication.
PRS4
SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR
OF ASTHMA EXACERBATION IN A MANAGED CARE
POPULATION
Stephenson JJ1, Quimbo RA1, Dai D1, Gutierrez B2
1HealthCore Inc,Wilmington, DE, USA, 2AstraZeneca,Wilmington,
DE, USA
OBJECTIVES: To assess whether sub-acute lack of asthma
control (SALAC) and its components, high SABA use and out-
patient asthma visits, predict subsequent asthma exacerbations in
a managed care population. METHODS: The HealthCore Inte-
grated Research Database was used to identify asthmatics, aged
6–64, with 3 years continuous enrollment from January 1, 2003–
December 31, 2005. Study inclusion criteria: 32 outpatient visits
or 31 hospitalization/emergency department (ED) visit with
asthma diagnosis (ICD-9-CM 493.xx) in a year. SALAC deﬁni-
tion: >4 outpatient asthma visits or >5 SABA prescriptions per
year. Annual acute asthma exacerbation (AAE) deﬁnition: 31
hospitalization/ED visit with primary asthma diagnosis or oral
corticosteroid burst. Separate generalized estimating equations
(GEEs) modeled risk of subsequent year AAEs, as a function of:
a) age, gender, geographic region, prior year AAEs and SALAC
and b) age, gender, geographic region, prior year AAEs and high
SABA use/outpatient asthma visits, to determine the independent
impact of prior year SALAC and its components on subsequent
year AAEs. RESULTS: Of 35,806 asthmatics, 47% were male
with mean age 31.6  17.9 years. During 2003–2005, 12.1% of
patients exhibited SALAC, 5.7% had high SABA use, 7.1% high
outpatient asthma visits and the SABA use/outpatient asthma
visit overlap averaged 0.7%. GEE results indicate that, control-
ling for all other variables, prior year SALAC is associated with
increased risk of subsequent year AAE (OR 1.60, 95% CI 1.51–
1.69; p < 0.0001). High outpatient asthma visits and SABA use
are each associated with increased risk of subsequent year AAE
(OR 1.34, 95% CI 1.25–1.44, p < 0.0001 and OR 1.85, 95%
CI 1.72–2.00, p < 0.0001, respectively). CONCLUSIONS: This
study demonstrates that SALAC and its components, high SABA
use and outpatient asthma visits, exhibit signiﬁcant effects in
predicting subsequent AAEs. Use of SALAC may help health
plans identify opportunities to simultaneously improve members’
asthma control and reduce health care utilization associated with
asthma exacerbations.
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Several studies have estimated the incidence and prevalence of
atopic conditions separately. Relatively few attempts have been
made to estimate the extent of co-existence of multiple atopic
conditions. OBJECTIVES: To estimate the age-speciﬁc incidence
and lifetime prevalence of eczema, rhinitis and asthma, alone or
in combination. METHODS: Using General Practice Research
Database (GPRD), a birth cohort of patients registered with UK
general practice within a year following birth and treated in the
same practice for the next twenty years was identiﬁed. The
incidence rate of an atopic condition each year following birth
and the lifetime prevalence of each atopic condition alone or in
combination with others was estimated. RESULTS: Among the
3 conditions, eczema had the highest cumulative incidence of
154.4 per 1000 patients (95%CI:153–156) followed by asthma
(126.3;(95%CI:125–128)) and rhinitis (60;(95%CI:59–61)), by
the age of 20 years. One in three patients diagnosed with eczema
and one in six patients diagnosed with asthma had their condi-
tion diagnosed by the age of 2 years. Eczema also had the highest
lifetime prevalence of clinician-diagnosed disease at 21.1%
(95%CI:20.0–21.3) followed by asthma (15.5%;(95%CI:15.3–
15.6%)) and rhinitis (9.4%;(95%CI:9.3–9.5)). The median age
of diagnosis was 8 years for eczema (IQR:2–20) and asthma
(IQR:3–16), and 16 years for rhinitis (IQR:10–25). 36.3%
(95%CI:36.1–36.5) of children were suffering from at least one
atopic condition and 9.8% (95%CI:9.6–9.9%) were diagnosed
with at least two. About 1.5% of patients were diagnosed with
all three conditions. Among these 32%, 30% and 10% had
eczema, asthma and rhinitis as their herald condition respec-
tively; the remaining 28% having their ﬁrst two atopic conditions
diagnosed at the same age. CONCLUSIONS: Eczema and
asthma showed high co-prevalence and high incidence rates in
early childhood. Among patients developing all three conditions,
a signiﬁcant proportion was diagnosed with at least two of them
by the age of ten years. There is likely to be more than one
variation of the ‘allergic march’ in those with co-morbid allergic
disease.
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